This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

WebMD Appoints Pharmaceutical And Consumer Healthcare Industry Innovator Cavan M. Redmond As New CEO

NEW YORK, June 1, 2012 /PRNewswire/ -- WebMD Health Corp. (NASDAQ: WBMD), the leading source of health information, announced today that Cavan M. Redmond has been appointed as its new Chief Executive Officer and as a member of its Board of Directors, effective May 31, 2012. Mr. Redmond, 51, joins WebMD from Pfizer Inc., the world's largest research-based pharmaceutical company, where he most recently served as Group President, Animal Health, Consumer Healthcare and Corporate Strategy and as a member of Pfizer's Executive Leadership Team. He was responsible for two diverse businesses while leading Pfizer's enterprise-wide Strategy, R&D Portfolio Management and Analysis, Global Commercial Operations and Continuous Improvement.

"Cavan brings unparalleled expertise and leadership in both biopharmaceutical and consumer healthcare to WebMD, and we are excited to welcome him to the WebMD team," said Martin J. Wygod, Chairman, WebMD. "He has a successful track record in identifying and leveraging new revenue opportunities, driving efficiency and establishing sustainable growth platforms. Along with our experienced management team, I have great confidence that Cavan will take WebMD to the next level. Cavan's proven ability to drive strategy and leverage the value of brands will be invaluable as WebMD continues to define and lead the market for digital health information."

Mr. Redmond has more than 20 years of healthcare experience encompassing a broad range of global healthcare businesses including biotechnology, pharmaceuticals, consumer healthcare and infant nutritionals. Mr. Redmond is a global healthcare strategist with a demonstrated ability to implement complex strategies in highly competitive and regulated markets. His strength in new product development, marketing, strategy and technology has resulted in a proven track record of building global brands, starting new businesses and reenergizing existing businesses. His biopharmaceutical experience also includes leading global strategic marketing, marketing research and analytics, new product marketing and multi-channel marketing programs. Prior to Pfizer's acquisition of Wyeth, Mr. Redmond served as the first Executive Vice President and General Manager of Wyeth's high-growth BioPharma Business Unit where he was responsible for the creation of the global biopharma business and grew the business significantly.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.24 -0.41%
FB $117.81 -0.21%
GOOG $701.43 0.82%
TSLA $211.53 -4.96%
YHOO $36.94 2.61%


Chart of I:DJI
DOW 17,660.71 +9.45 0.05%
S&P 500 2,050.63 -0.49 -0.02%
NASDAQ 4,717.0940 -8.5450 -0.18%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs